Billionaires Bill Ackman, Jeremy Grantham, and Cliff Asness Are Piling Into This AI Stock the Market Is Severely Undervaluing

Billionaire investors (Ackman, Grantham, and Asness) added to Microsoft, with Pershing Square buying ~ $2B of MSFT, GMO taking it as top holding, and AQR increasing its stake by 60%. The article argues MSFT is undervalued at ~21x earnings despite strong growth, citing Azure revenue up 40% y/y, enterprise software revenue up 17% y/y, and a $627B contracted-revenue backlog with ~25% to be recognized over 12 months. With Copilot adoption (20M paid commercial users) seen as a key upside lever, the news is constructive for long-term positioning but likely only modest near-term price impact.

Analysis

The near-term readthrough is more about positioning than fundamentals: a high-quality megacap with visible recurrence can keep grinding higher, but the first-order opportunity may already be in the name’s relative underownership versus the AI basket, not in a fresh information edge. If the multiple expands from here, the biggest beneficiaries are likely not just MSFT holders but adjacent ecosystem names that ride a stronger enterprise AI budget cycle—semis, data-center power, and infrastructure software. The losers are the lower-ROIC AI monetization stories that need sustained spending to justify their valuations; MSFT’s distribution advantage can pressure vendors that sell copilots, workflow, or cloud layer solutions without a captive install base.

The real catalyst path is 1-3 months, not days: the market will care less about marketing around AI attach rates and more about whether Azure growth can stay ahead of normalization while incremental AI capex stops compressing FCF. If management proves that the backlog converts without disproportionate margin drag, the stock can rerate; if not, the “cheap at 21x” narrative breaks quickly because multiple support depends on durable margin expansion, not just revenue growth. Over 6-18 months, the key variable is whether Copilot becomes a material seat-price uplift or just a feature bundle that mainly protects retention.

Contrarian view: consensus may be underestimating how much of MSFT’s valuation is already tied to an AI premium, so ‘undervalued’ may simply mean ‘less overpriced than peers.’ The market could be correctly skeptical until there is hard evidence of net new operating leverage after AI infrastructure spend, especially if competitors use open ecosystems and aggressive pricing to slow cloud share gains. Regulatory risk is also non-trivial: any renewed scrutiny around bundling, cloud concentration, or AI distribution could cap multiple expansion even if fundamentals remain solid.

Key Decisions for Investors

• Long MSFT on 1-3 month pullbacks; best entry is after any post-earnings volatility when the market can verify Azure growth and FCF conversion rather than pay for narrative. Risk/reward favors a slow compounder if the stock can hold above the prior 3-6 month range; thesis breaks if management signals margin dilution from AI capex persists into the next guide.
• Pair trade: long MSFT / short CRM or SNOW over 1-6 months. The setup is that MSFT can monetize AI through distribution and pricing power, while the shorts rely more on proving product relevance and sustained spend; cover if either short shows accelerating net retention or margin inflection.
• Watchlist long: NVDA on any MSFT-led enterprise AI reacceleration, but only if hyperscaler capex commentary confirms rising GPU demand. This is a second-order beneficiary rather than the primary trade; falsify if cloud capex growth flattens while AI attach rates stay small.
• If you need hedged tech exposure, prefer MSFT over XLK/QQQ as the core holding and use the index as the hedge leg. The relative value thesis is that MSFT offers better downside protection than the broader mega-cap complex if rates back up or AI enthusiasm cools.